<DOC>
	<DOCNO>NCT01920191</DOCNO>
	<brief_summary>RATIONALE : IMA 950 multi tumour-associated peptide ( TUMAPs ) vaccine , peptide identify primary glioblastoma multiforme ( GBM ) cell . Poly-ICLC potent vaccine adjuvant broad innate adaptive immune enhance effect . IMA 950 Poly-ICLC administer patient alongside standard primary therapy glioblastoma . This include alkylating drug temozolomide ( TMZ ) . Effective vaccine-induced immune response associate prolonged survival observe glioblastoma patient TMZ adjuvant therapy , suggest possible synergistic effect . A second component glioblastoma standard treatment external beam irradiation tumor site post-surgery . As side effect , potentially beneficial tumor-infiltrating immune cell may also kill radiation . However , combination radiation immunotherapy suggest favorable pre-clinical model .</brief_summary>
	<brief_title>Phase I/II Trial IMA950 Multi-peptide Vaccine Plus Poly-ICLC Glioblastoma</brief_title>
	<detailed_description>OBJECTIVES Primary - Tolerability safety IMA950 adjuvanted Poly-ICLC give together temozolomide , use CTCAE V 4.0 . - Immunogenicity IMA950 plus Poly-ICLC give together temozolomide . Secondary - 6 , 9 month progression free survival ( PFS ) use gadolinium enhance MRI clinical assessment accord revise RANO criterion - Overall survival ( OS ) - Immunologic endpoint ( correlation clinical immunological response ) : - evaluation peptide immunogenicity tetramer stain - analysis memory , activation home marker expression tetramer positive cell - analysis cytokine secretion proliferation antigen-specific CD4 CD8 T cell - analysis presence T regulatory myeloid-derived suppressor cell - The immunological analysis perform : - peripheral blood mononuclear cell ( PBMC ) - culture skin punch biopsy delayed-type hypersensitivity ( DTH ) site - tumor-infiltrating lymphocyte ( TIL ) brain tissue available recurrence OUTLINE This monocentric , open label , one cohort , safety immunogenicity , Phase I/II study . A maximum 16 HLA-A2 positive patient newly diagnose glioblastoma enrol study treatment radiation therapy concurrent temozolomide . All patient receive dose IMA950 Poly-ICLC follow vaccination schedule comprise Vaccination Induction Phase 4 intensive vaccination , follow Vaccination Maintenance Phase five vaccination longer period . The Vaccination Induction Phase start minimum 7 day final radiotherapy/TMZ dose CRT 28 day ( +7 day ) prior first schedule dose adjuvant TMZ . This ensure 4 vaccination Induction Phase administer week immunosuppressive therapy ( i.e . combine radiotherapy temozolomide ) finish week prior start adjuvant TMZ . Two Phases : Induction phase , patient receive first 4 dos Poly ICLC mix IMA 950 Peptide base vaccine ( subcutaneously IM ) day 1,8,15 , 21 absence unacceptable toxicity disease progression . Maintenance Phase , patient receive Poly ICLC mix IMA 950 Peptide base vaccine ( SC IM ) day 21 adjuvant temozolomide cycle absence unacceptable toxicity disease progression . Immunomonitoring assessment perform 8 time point blood sample collection one DTH site analysis ( vaccination 5 ) . Brain MRI perform every two month disease assessment . N.B . : An amendment accept Swissmedic Local Ethics committee september 2014 , suboptimal immunomonitoring preliminary assessment , schedule administration change order improve immunogenicity vaccine , follow : - injection mixed peptide adjuvant Poly ICLC - 4 vaccination induction phase instead 6 - one site injection ( thigh ) - two arm next 10 patient include equally divide 2 group : one group vaccinate subcutaneously intramuscularly .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Poly I-C</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>1 . Histological documentation glioblastoma . For experimental purpose , 5 additional grade III astrocytoma may include ( case include endpoint analysis ) . 2 . Patients must complete radiation therapy concomitant temozolomide . 3 . HLAA2 positive . 4 . Eastern Cooperative Oncology Group performance status 0 1 ( Appendix1 ) . 5 . Age &gt; 18 year , life expectancy least 4 month . 6 . Patient must stable decrease dose steroid , maximal dose Dexamethasone 4mg/day . 7 . Adequate bone marrow , liver kidney function . 8 . Hepatitis B serology negative ( HBcAgseronegative ) 9 . Written ( sign date ) inform consent . Capable cooperate standard therapy IMA950 PolyICLC vaccination followup . 1 . Any vaccination give within 2 week first IMA950 vaccination . 2 . History cardiac disease : congestive heart failure &gt; New York heart association class 2 , active CAD , cardiac require antiarrhythmic therapy uncontrolled hypertension . 3 . History HIV infection chronic hepatitis B C clinical active infection . 4 . Patients evidence history bleed diathesis . 5 . Pregnant potentially pregnant patient . Women childbearing age must test pregnancy ( serum urine HCG ) treatment must contemplate pregnancy study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Glioblastoma</keyword>
</DOC>